Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00624468
Registration number
NCT00624468
Ethics application status
Date submitted
15/02/2008
Date registered
27/02/2008
Date last updated
17/02/2016
Titles & IDs
Public title
Atacicept in Subjects With Optic Neuritis
Query!
Scientific title
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Query!
Secondary ID [1]
0
0
28156
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Optic Neuritis
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Eye
0
0
0
0
Query!
Diseases / disorders of the eye
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Atacicept
Treatment: Drugs - Placebo matched to atacicept
Experimental: Atacicept -
Placebo Comparator: Placebo -
Treatment: Drugs: Atacicept
Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
Treatment: Drugs: Placebo matched to atacicept
Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Last Observed Value (LOV)
Query!
Assessment method [1]
0
0
The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by optical coherence tomography (OCT) measurements and were then averaged over 12 sectors. The change in RNFL thickness at LOV visit was calculated as RNFL thickness at LOV minus RNFL thickness at baseline.
Query!
Timepoint [1]
0
0
Baseline, LOV (Week 48)
Query!
Secondary outcome [1]
0
0
Difference in Retinal Nerve Fibre Layer (RNFL) Thickness Between the Affected Eye and Fellow Eye
Query!
Assessment method [1]
0
0
The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by optical coherence tomography (OCT) measurements and was then averaged over 12 sectors. Difference was calculated as RNFL thickness in affected eye minus RNFL thickness in fellow eye.
Query!
Timepoint [1]
0
0
Weeks 12, 24 and 36
Query!
Secondary outcome [2]
0
0
Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Weeks 12 and 24
Query!
Assessment method [2]
0
0
The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by OCT measurements and was then averaged over 12 sectors. The change in RNFL thickness at Weeks 12 and 24 was calculated as RNFL thickness at Weeks 12 and 24 minus RNFL thickness at baseline, respectively.
Query!
Timepoint [2]
0
0
Baseline, Weeks 12 and 24
Query!
Secondary outcome [3]
0
0
Change From Baseline in Macular Thickness at 3 Millimeter (mm) Around Fovea in the Affected Eye at Weeks 12, 24 and 36
Query!
Assessment method [3]
0
0
The change in macular thickness at 3 mm around fovea in the affected eye at Weeks 12, 24 and 36 was calculated as macular thickness at 3 mm in the affected eye at Weeks 12, 24 and 36 minus macular thickness at 3 mm in the affected eye at baseline, respectively.
Query!
Timepoint [3]
0
0
Baseline, Weeks 12, 24 and 36
Query!
Secondary outcome [4]
0
0
Change From Baseline in Macular Thickness at 6 Millimeter (mm) Around Fovea in the Affected Eye at Weeks 12, 24 and 36
Query!
Assessment method [4]
0
0
The change in macular thickness at 6 mm around fovea in the affected eye at Weeks 12, 24 and 36 was calculated as macular thickness at 6 mm in the affected eye at Weeks 12, 24 and 36 minus macular thickness at 6 mm in the affected eye at baseline, respectively.
Query!
Timepoint [4]
0
0
Baseline, Weeks 12, 24 and 36
Query!
Secondary outcome [5]
0
0
Change From Baseline in Macular Volume in the Affected Eye at Weeks 12, 24 and 36
Query!
Assessment method [5]
0
0
The change in macular volume in the affected eye at Weeks 12, 24 and 36 was calculated as macular volume in the affected eye at Weeks 12, 24 and 36 minus macular volume in the affected eye at baseline, respectively.
Query!
Timepoint [5]
0
0
Baseline, Weeks 12, 24 and 36
Query!
Secondary outcome [6]
0
0
Low-Contrast Letter Acuity: Total Number of Letters Correctly Identified
Query!
Assessment method [6]
0
0
Low-contrast letter acuity was measured by using the Sloan Charts at 1.25 fraction (%) and 2.5%. Sloan letters are a set of optotypes used to test visual acuity. Total number of letters correctly identified in the affected and fellow eye were reported. The possible Sloan Chart range is 0 to 70. More the number of letters identified, better is the visual acuity.
Query!
Timepoint [6]
0
0
Weeks 12, 24 and 36
Query!
Secondary outcome [7]
0
0
Contrast Sensitivity: Total Number of Letters Correctly Identified
Query!
Assessment method [7]
0
0
Contrast Sensitivity was measured using the Pelli-Robson Charts. Pelli-Robson chart is used for clinical measurement of contrast sensitivity and determines the contrast required to read large letters of a fixed size. Total number of letters correctly identified in the affected and fellow eye were reported. The total possible range is 0 to 48. More the number of letters identified, better is the contrast sensitivity.
Query!
Timepoint [7]
0
0
Weeks 12, 24 and 36
Query!
Secondary outcome [8]
0
0
Contrast Sensitivity: Score Line
Query!
Assessment method [8]
0
0
Contrast sensitivity was measured using the Pelli-Robson charts with letters arranged in groups of 3. Pelli-Robson chart is used for clinical measurement of contrast sensitivity and determines the contrast required to read large letters of a fixed size. The possible score line range is 0 (visual disability) to 16 (normal contrast sensitivity).
Query!
Timepoint [8]
0
0
Weeks 12, 24 and 36
Query!
Secondary outcome [9]
0
0
Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) Second Clinical Attack
Query!
Assessment method [9]
0
0
Conversion to CDMS was defined as experiencing a second clinical attack meeting all of the following criteria: (a) Neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both (i) Neurological abnormality separated by at least 30 days from onset of a preceding clinical event, and (ii) Neurological abnormality lasting for at least 24 hours; (b) Absence of fever or known infection (fever with temperature [axillary, orally or intraauricularly] greater than 37.5 degree Celsius/99.5 degree Fahrenheit); (c) Objective neurological impairment, correlating with the participant's reported symptoms, defined as either (i) Increase in at least 1 of the functional systems of the Expanded Disability Status Score (EDSS), or (ii) Increase of the total EDSS score. EDSS assesses disability in 8 functional systems and total score ranges from 0 (normal) to 10 (death due to MS). Percentage of participants converting to CDMS (second clinical attack) was reported.
Query!
Timepoint [9]
0
0
From baseline (Study Day 1) up to Week 36
Query!
Eligibility
Key inclusion criteria
- Diagnosis of unilateral symptomatic optic neuritis as first clinical manifestation
within 28 days between onset of symptoms and study Day 1
- Other protocol defined inclusion criteria could apply
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
60
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Pre treatment with immunosuppressants and immunomodulating drugs
- Relevant cardiac, hepatic and renal diseases
- Clinical significant abnormalities in blood cell counts and immunoglobulin levels
- Clinical significant acute or chronic infections
- Other protocol defined exclusion criteria could apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/01/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
34
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Research Site - Parkville
Query!
Recruitment postcode(s) [1]
0
0
- Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Michigan
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Pennsylvania
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Texas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Vermont
Query!
Country [9]
0
0
Belgium
Query!
State/province [9]
0
0
Bruxelles
Query!
Country [10]
0
0
Canada
Query!
State/province [10]
0
0
British Columbia
Query!
Country [11]
0
0
Canada
Query!
State/province [11]
0
0
Ontario
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
Quebec
Query!
Country [13]
0
0
Czech Republic
Query!
State/province [13]
0
0
Hradec Kralove
Query!
Country [14]
0
0
Czech Republic
Query!
State/province [14]
0
0
Olomouc
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Paris
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Freiburg
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Munich
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Tübingen
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Würzburg
Query!
Country [20]
0
0
Lebanon
Query!
State/province [20]
0
0
Beyrouth
Query!
Country [21]
0
0
Lebanon
Query!
State/province [21]
0
0
Dbayeh
Query!
Country [22]
0
0
Spain
Query!
State/province [22]
0
0
Barcelona
Query!
Country [23]
0
0
Spain
Query!
State/province [23]
0
0
Sevilla
Query!
Country [24]
0
0
Spain
Query!
State/province [24]
0
0
Valencia
Query!
Country [25]
0
0
Switzerland
Query!
State/province [25]
0
0
Lausanne
Query!
Country [26]
0
0
United Kingdom
Query!
State/province [26]
0
0
London
Query!
Country [27]
0
0
United Kingdom
Query!
State/province [27]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
EMD Serono
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Merck KGaA, Darmstadt, Germany
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study was intended to evaluate the efficacy, safety and tolerability of atacicept
compared to placebo and to explore the neuroprotective effect of atacicept as assessed by OCT
in subjects with ON as CIS. The study was randomized. Study medication was administered via
subcutaneous (under the skin) injections.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00624468
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Responsible
Query!
Address
0
0
EMD Serono, an affiliate of MerckKGaA, Darmstadt, Germany
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00624468
Download to PDF